fp-1039
Recombinant proteinexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00687505)
Timeline
Indications
Mechanism of action
- Acidic fibroblast growth factorINHIBITOR
FGF1 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297755 ↗
Also known as
- fp-1039
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01244438 | Phase 2 | Jan 1, 2011 | Five Prime Therapeutics, Worldwide Clinical Trials |
| NCT00687505 | Phase 1 | Jul 1, 2008 | Five Prime Therapeutics, Parexel |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Five Prime Therapeutics | For profit | 2 | 2 | 2 | 2008 |
| Parexel | For profit | 1 | 0 | 1 | 2008 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2011 |
3 organizations
Page 1 / 1